Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

933589

Sigma-Aldrich

NanoFabTx™ NanoFlash PEG Lipid Mix

for CIJ synthesis of PEGylated liposomes

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352211
NACRES:
NA.21

Quality Level

100

storage temp.

−20°C

Application

NanoFabTx™ NanoFlash PEG Lipid Mix a ready-to-use nanoformulation lipid blend that includes lyophilized lipids and step-by-step instructions for synthesizing PEGylated liposomes for small molecule drug delivery applications. Lipid-based formulations are widely used for drug delivery and enable improved therapeutic efficacy of a range of drug types PEGylated liposomes are capable of encapsulating both hydrophilic and lipophilic compounds and are an effective mechanism to increase the efficiency of drug delivery by prolonging the lifetime of the drug-encapsulated liposome.
This lipid mix has been curated and designed for flash nanoprecipitiaton (FNP) synthesis using a confined impingement jet (CIJ) mixer, such as the NanoFabTx™ NanoFlash CIJ Mixer, and detailed step-by-step instructions are provided.

Features and Benefits

  • A ready-to-use nanoformulation lipid blend for the synthesis of PEGylated liposomes
  • Step-by-step protocols (extrusion and microfluidics) developed and tested by our formulation scientists
  • Flexible synthesis tool to create uniform and reproducible liposomes
  • Optimized to make liposomes around 100 nm with low polydispersity
  • Optimized lipid blend for stealth PEGylated liposomes for small molecule encapsulation
The NanoFabTx™- PEG Lipid Mix provides reagents and protocols for extrusion and microfluidics to synthesize liposomes for drug delivery research application. This reagent kit can be combined with the NanoFabTx™ Microfluidic - nano device kit (Cat.No. 91153) for microfluidic synthesis of PEGylated liposomes. Comprehensive protocols for liposome synthesis are included:

  • A lipid film hydration and extrusion protocol
  • A microfluidics protocol using commercial platforms or syringe pumps
The microfluidics protocol included with this product uses the NanoFabTx™ device kit (911593). These kits come with the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

Legal Information

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCV0299

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Which polymers can make nanoparticulate drug carriers long-circulating?
VP, Torchilin, et al.
Advanced Drug Delivery Reviews, 16, 141?155-141?155 (1995)
Jing Han et al.
Journal of pharmaceutical sciences, 101(10), 4018-4023 (2012-07-11)
Johnson and Prud'homme (2003. AICHE J 49:2264-2282) introduced the confined impingement jets (CIJ) mixer to prepare nanoparticles loaded with hydrophobic compounds (e.g., drugs, inks, fragrances, or pheromones) via flash nanoprecipitation (FNP). We have modified the original CIJ design to allow
D Papahadjopoulos et al.
Proceedings of the National Academy of Sciences of the United States of America, 88(24), 11460-11464 (1991-12-15)
The results obtained in this study establish that liposome formulations incorporating a synthetic polyethylene glycol-derivatized phospholipid have a pronounced effect on liposome tissue distribution and can produce a large increase in the pharmacological efficacy of encapsulated antitumor drugs. This effect
Daryl C Drummond et al.
Cancer research, 66(6), 3271-3277 (2006-03-17)
Liposome formulations of camptothecins have been actively pursued because of the potential for significant pharmacologic advantages from successful drug delivery of this important class of anticancer drugs. We describe nanoliposomal CPT-11, a novel nanoparticle/liposome construct containing CPT-11 (irinotecan) with unprecedented
L D Mayer et al.
Biochimica et biophysica acta, 1025(2), 143-151 (1990-06-27)
Studies from this laboratory (Mayer et al. (1986) Biochim. Biophys. Acta 857, 123-126) have shown that doxorubicin can be accumulated into liposomal systems in response to transmembrane pH gradients (inside acidic). Here, detailed characterizations of the drug uptake and retention
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service